Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metadoxine for Oxidative Stress in NAFLD and Prediabetes
NCT02051842Phase 4Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Jan 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Metadoxine in non-alcoholic fatty liver disease (NAFLD), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Primary endpoint: Oxidative stress. Status: unknown.
02
Drugs
Metadoxine
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02051842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051842.